Скачать или смотреть Shaily Engineering Plastics Q2 FY 2025-26 Updates

Shaily Engineering Plastics just posted a 1,000 BPS margin expansion in their Q2 FY 26 results.

Why? The global GLP-1 / Semaglutide (weight-loss drug) boom.
In Q2 FY26:
Revenue: +34%
EBITDA: +100%
Profit: +134%

Their healthcare segment, driven by injector pens for weight-loss drugs, grew 163% YoY. They are a key supplier to 24 global players and are doubling capacity to 80 MILLION pens.

This is a core part of my “Next Big Thing” theme. Want the full deep dive on the GLP-1 market?

SUBSCRIBE! We drop the full video at 500 subscribers!

#shorts #investing #semaglutide #stockmarket #shailyengineering #ozempic #wegovy #finance #stocks

---
Disclaimer: This video is for informational and educational purposes only. It is not financial advice. Please conduct your own research before investing.